What is the 13F Pro Quality Score for ROIV?

13F Pro ranks Roivant Sciences Ltd. (ROIV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ROIV's current score at https://13fpro.ai/research/ROIV (free sign-up required for the full ranking).

Which hedge funds own the most ROIV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ROIV include FMR, MORGAN STANLEY, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ROIV as soon as new 13F filings post.

Where does 13F Pro source ROIV data?

All Roivant Sciences Ltd. fundamentals and ownership data come directly from SEC EDGAR. Roivant Sciences Ltd. files with the SEC under CIK 1635088. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ROIV in?

Roivant Sciences Ltd. (ROIV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ROIV research updated on 13F Pro?

ROIV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Roivant Sciences Ltd.(ROIV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1635088 ROIV stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ROIV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Roivant Sciences Ltd. (ROIV), a Healthcare sector company. ROIV is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2026), Roivant Sciences Ltd. reports quarterly revenue of $2.5M, net income of $303.0M, free cash flow of $-165.1M. Top institutional holders of ROIV by reported 13-F value include FMR, MORGAN STANLEY, BlackRock,, based on the most recent SEC filings. ROIV trades on the Nasdaq exchange and files with the SEC under CIK 1635088. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ROIV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Roivant Sciences Ltd. directly from SEC EDGAR. Roivant Sciences Ltd.'s 13F Pro composite quality score has ranged between 7 and 43 since 2022, currently 24.3 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q4 2026

$2.5M

Net Income

Q4 2026

$303.0M

Free Cash Flow

Q4 2026

$-165.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-71.6% YoY

$8.3MFY 2026

FY23 $31.5MFY24 $32.7MFY25 $29.1MFY26 $8.3M

Net Income

-74.3% YoY

$-299.8MFY 2026

FY23 $-1.01BFY24 $4.35BFY25 $-172.0MFY26 $-299.8M

Operating Income

+48.7% YoY

$-515.1MFY 2026

FY23 $-906.8MFY24 $4.50BFY25 $-1.00BFY26 $-515.1M

EPS (Diluted)

-125.0% YoY

$-0.54FY 2026

FY23 $-1.42FY24 $5.23FY25 $-0.24FY26 $-0.54

Total Assets

+5.0% YoY

$5.71BFY 2026

FY23 $2.39BFY24 $7.22BFY25 $5.44BFY26 $5.71B

Total Debt

—FY 2026

FY23 $416.2MFY24 $442.6MFY25 —FY26 —

Op. Cash Flow

+10.6% YoY

$-750.3MFY 2026

FY23 $-843.4MFY24 $-765.3MFY25 $-839.5MFY26 $-750.3M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020
Revenue	$8.3M -71.6%	$29.1M -11.2%	$32.7M +3.8%	$31.5M +32.5%	$23.8M	—
Net Income	$-299.8M -74.3%	$-172.0M -104.0%	$4.35B +531.0%	$-1.01B -24.7%	$-809.2M	—
Operating Income	$-515.1M +48.7%	$-1.00B -122.3%	$4.50B +595.9%	$-906.8M +15.3%	$-1.07B	—
EPS (Diluted)	$-0.54 -125.0%	$-0.24 -104.6%	$5.23 +468.3%	$-1.42	—	—
Total Assets	$5.71B +5.0%	$5.44B -24.7%	$7.22B +202.2%	$2.39B -7.7%	$2.59B	—
Total Debt	—	—	$442.6M +6.3%	$416.2M +144.4%	$170.3M	—
Operating Cash Flow	$-750.3M +10.6%	$-839.5M -9.7%	$-765.3M +9.3%	$-843.4M -52.8%	$-552.1M	—

AI Insight: ROIV Ratio Trends

Roivant swung to profitability in Q1 2026 with ROE of 26.8% and ROIC of 36.7%, reversing four consecutive quarters of negative returns.

• ROE recovered to 26.8% in Q1 2026 from -24.9% in Q4 2025; ROA jumped to 21.2% from -20.3%.

• ROIC turned positive at 36.7% in Q1 2026, reversing deterioration from -31.8% in Q4 2025.

• Q1 2024 showed 172.8% NPM, but margins data sparse across recent quarters limits trend visibility.

⚠ TTM metrics remain deeply negative (ROE -6.6%, ROA -5.2%, ROIC -11.4%), suggesting Q1 2026 is isolated gain.

⚠ Sustainability of Q1 2026 profitability is unclear given volatile quarterly swings throughout 2024–2025.

Get alerted when ROIV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Roivant Sciences Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ROIV

FMR LLC
$2.2B77,981,253 sh
MORGAN STANLEY
$1.4B51,828,325 sh
BlackRock, Inc.
$1.2B44,254,260 sh
QVT Financial LP
$697.0M25,161,237 sh
UBS Group AG
$626.6M22,619,472 sh
VANGUARD CAPITAL MANAGEMENT LLC
$572.9M20,680,572 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$549.5M19,838,698 sh
STATE STREET CORP
$448.4M16,186,613 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$354.4M12,794,097 sh
GOLDMAN SACHS GROUP INC
$307.8M11,111,591 sh

Fund	Value	Shares
FMR LLC	$2.2B	77,981,253
MORGAN STANLEY	$1.4B	51,828,325
BlackRock, Inc.	$1.2B	44,254,260
QVT Financial LP	$697.0M	25,161,237
UBS Group AG	$626.6M	22,619,472
VANGUARD CAPITAL MANAGEMENT LLC	$572.9M	20,680,572
VANGUARD PORTFOLIO MANAGEMENT LLC	$549.5M	19,838,698
STATE STREET CORP	$448.4M	16,186,613
ADAGE CAPITAL PARTNERS GP, L.L.C.	$354.4M	12,794,097
GOLDMAN SACHS GROUP INC	$307.8M	11,111,591

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ROIV on your watchlist

Track score changes the day Roivant Sciences Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ROIV a good stock to buy?

13F Pro's AI-powered analysis of Roivant Sciences Ltd. (ROIV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ROIV are available on the ROIV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ROIV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ROIV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Roivant Sciences Ltd.'s investment landscape.